# A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

> **NCT03242018** · PHASE3 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 277 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Chronic Kidney Disease Stage 4

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sotagliflozin

## Key facts

- **NCT ID:** NCT03242018
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2019-05-16
- **Final completion:** 2019-12-11
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2021-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242018, "A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03242018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*